Keywords
renal cysts
system review
tetracycline
volume reduction
How to Cite
Abstract
Objective: Percutaneous aspiration sclerotherapy is indicated for treatment of symptomatic renal cysts. The efficacy and safety of the different sclerosing agents have been sources of debate and disagreement. The purpose of this study was to assess the efficacy and safety of using tetracycline aspiration sclerotherapy in a systematic review of the literature.
Materials and Methods: A systematic search was conducted on the following electronic databases: Cochrane Central Register of Controlled Trials, EMBASE, PubMed and HERDIN (until November 2017). Studies of cyst volume reduction after tetracycline aspiration sclerotherapy were included for full text evaluation. The quality of the studies and the risk of bias were assessed independently by the authors, based on the Cochrane Handbook for Systematic Reviews of Interventions.
Results: Three studies were included for full-text assessment. They included 87 patients. Overall, risk of bias was high. Complete renal cyst disappearance ranged between 29%-100% after a follow-up period of 3-36 months. Partial success/>50% renal cyst reduction ranged between 85.7%-100%. Complications were minor and self-limited, postoperative procedural pain occurred most frequently.
Conclusion: The authors found good results with respect to efficacy and safety after tetracycline aspiration sclerotherapy of renal cysts. However, due to high risk of bias in the included studies, definite conclusions regarding efficacy could not be drawn.